In a trial, Gossamer Bio's PAH treatment candidate seralutinib reduced the resistance blood faces moving into the lungs over ...
Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback